Catherine E Oldenburg1, Sachin Jain2, Kenneth H Mayer3, Matthew J Mimiaga4. 1. Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States; The Fenway Institute, Fenway Community Health, Boston, MA, United States. Electronic address: ceo242@mail.harvard.edu. 2. The Fenway Institute, Fenway Community Health, Boston, MA, United States; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA, United States. 3. The Fenway Institute, Fenway Community Health, Boston, MA, United States; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA, United States; Department of Global Health and Population, Harvard School of Public Health, Boston, MA, United States. 4. Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA, United States; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States.
Abstract
BACKGROUND: Men who have sex with men (MSM) who use crystal methamphetamine (CM) are at increased risk for HIV infection. Post-exposure prophylaxis (PEP) is a useful HIV prevention strategy if individuals are able to identify high-risk exposures and seek timely care, however to date there has been limited data on the use of PEP by CM users. METHODS A: Retrospective cohort study of all PEP prescriptions (N=1130 prescriptions among 788 MSM) at Fenway Community Health in Boston, MA was undertaken. Multivariable models were used to assess the association between CM use during exposure (7.4% used CM during exposure) and chronically (7.4% of MSM were chronic CM users) and individual-level and event-level outcomes among MSM who used PEP at least once. RESULTS: Compared to those who had not used CM, MSM PEP users who used CM more frequently returned for repeat PEP (aOR 5.13, 95% CI 2.82 to 9.34) and were significantly more likely to seroconvert over the follow-up period (aHR 3.61, 95% CI 1.51 to 8.60). MSM who used CM had increased odds of unprotected anal intercourse as the source of exposure (aOR 2.12, 95% CI 1.16 to 3.87) and knowing that their partner was HIV infected (aOR 2.27, 95% CI 1.42 to 3.64). CONCLUSIONS: While MSM who use CM may have challenges accessing ART in general, these data highlight the fact that those who were able to access PEP subsequently remained at increased risk of HIV seroconversion. Counseling and/or substance use interventions during the PEP course should be considered for CM-using MSM.
BACKGROUND:Men who have sex with men (MSM) who use crystal methamphetamine (CM) are at increased risk for HIV infection. Post-exposure prophylaxis (PEP) is a useful HIV prevention strategy if individuals are able to identify high-risk exposures and seek timely care, however to date there has been limited data on the use of PEP by CM users. METHODS A: Retrospective cohort study of all PEP prescriptions (N=1130 prescriptions among 788 MSM) at Fenway Community Health in Boston, MA was undertaken. Multivariable models were used to assess the association between CM use during exposure (7.4% used CM during exposure) and chronically (7.4% of MSM were chronic CM users) and individual-level and event-level outcomes among MSM who used PEP at least once. RESULTS: Compared to those who had not used CM, MSM PEP users who used CM more frequently returned for repeat PEP (aOR 5.13, 95% CI 2.82 to 9.34) and were significantly more likely to seroconvert over the follow-up period (aHR 3.61, 95% CI 1.51 to 8.60). MSM who used CM had increased odds of unprotected anal intercourse as the source of exposure (aOR 2.12, 95% CI 1.16 to 3.87) and knowing that their partner was HIV infected (aOR 2.27, 95% CI 1.42 to 3.64). CONCLUSIONS: While MSM who use CM may have challenges accessing ART in general, these data highlight the fact that those who were able to access PEP subsequently remained at increased risk of HIV seroconversion. Counseling and/or substance use interventions during the PEP course should be considered for CM-using MSM.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Richard A Rawson; Michael J McCann; Frank Flammino; Steven Shoptaw; Karen Miotto; Chris Reiber; Walter Ling Journal: Addiction Date: 2006-02 Impact factor: 6.526
Authors: Albert Y Liu; Pravina V Kittredge; Eric Vittinghoff; H Fisher Raymond; Katherine Ahrens; Tim Matheson; Jennifer Hecht; Jeffrey D Klausner; Susan P Buchbinder Journal: J Acquir Immune Defic Syndr Date: 2008-02-01 Impact factor: 3.731
Authors: Beryl A Koblin; Marla J Husnik; Grant Colfax; Yijian Huang; Maria Madison; Kenneth Mayer; Patrick J Barresi; Thomas J Coates; Margaret A Chesney; Susan Buchbinder Journal: AIDS Date: 2006-03-21 Impact factor: 4.177
Authors: Catherine E Oldenburg; Jennifer A Mitty; Katie B Biello; Elizabeth F Closson; Steven A Safren; Kenneth H Mayer; Matthew J Mimiaga Journal: AIDS Behav Date: 2016-07
Authors: S Y Lin; N J Lachowsky; M Hull; A Rich; Z Cui; P Sereda; J Jollimore; K Stephenson; M Thumath; Jsg Montaner; E A Roth; R S Hogg; D M Moore Journal: HIV Med Date: 2016-08-01 Impact factor: 3.180
Authors: Matthew R Beymer; Robert E Weiss; Robert K Bolan; Ryan M Kofron; Risa P Flynn; David L Pieribone; Sonali P Kulkarni; Raphael J Landovitz Journal: Open Forum Infect Dis Date: 2017-04-04 Impact factor: 3.835
Authors: Michael Viamonte; Delaram Ghanooni; John M Reynolds; Christian Grov; Adam W Carrico Journal: Curr HIV/AIDS Rep Date: 2022-06-14 Impact factor: 5.495
Authors: Katie B Biello; Matthew J Mimiaga; Pablo K Valente; Nimish Saxena; Angela R Bazzi Journal: Curr HIV/AIDS Rep Date: 2021-04-27 Impact factor: 5.495
Authors: Elizabeth Kaplun; Richard J Martino; Kristen D Krause; Michael Briganti; Paul A D'Avanzo; Perry N Halkitis Journal: Int J Environ Res Public Health Date: 2022-01-09 Impact factor: 3.390